tiprankstipranks
AbbVie price target lowered to $195 from $200 at Wells Fargo
The Fly

AbbVie price target lowered to $195 from $200 at Wells Fargo

Wells Fargo lowered the firm’s price target on AbbVie to $195 from $200 and keeps an Overweight rating on the shares. The firm is not concerned about I&I pricing rebates, as Rinvoq and Skyrizi are still expected to drive high double-digit growth, and would be a buyer of the stock here, the analyst tells investors in a research note. At the same time, pipeline concerns make Wells Fargo see the need for M&A.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ABBV:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles